CLL is one of the most common forms of blood cancer and the majority of patients diagnosed with this disease are of advanced age. Many of these have concurrent diseases and therefore may not tolerate more aggressive therapy which is the standard in younger patients.
About the German CLL Study Group (GCLLSG)
Founded in 1996 and headed by Professor Dr. Michael Hallek, Director of the Department I of Internal Medicine at the University Hospital Cologne, the GCLLSG has been running various phase-III, phase- II, and phase-I trials in CLL with the goal to provide optimal treatment to patients suffering from this disease. Among those were landmark trials like the CLL8 trial which led to the current standard of care in physically fit patients with CLL. For many years, the German CLL Study Group has been aiming to improve not just the treatment of younger and physically fit patients, but also that of elderly and less fit patients. These patients are generally underrepresented in clinical trials although they significantly contribute to the population of CLL patients treated by doctors in daily practice. The German CLL Study Group is an independent non-profit research organization supported by the Deutsche Krebshilfe.
About the International Workshop of the GCLLSG
The German CLL Study group will host its bi annual workshop for the 10th time on the occasion of its 20th anniversary in Cologne. Over the past years this workshop has become a major international meeting for CLL research, with participants hailing from around the globe to share and expand their knowledge on CLL.
The meeting aims to bring together physicians and scientists from all over the world in a meeting format that encourages in-depth and open discussion about the future management of CLL. This evolution reflects the increasing interest in the treatment and research of the disease due to the major advances which have improved our understanding of CLL.
One of the key features of our workshops have always been to promote the presentation of the very best research and clinical data in CLL, whilst at the same time, encouraging emerging and younger CLL investigators to participate in a friendly and stimulating environment. It is very important that this atmosphere is continued within the goals of whilst being mindful of dealing with an expanding popular scientific Meeting.